TC /1-2305 JCH

NULL 11/23/05 DEC 01 1005 B

United States Patent and Trademark Office

P68318UST

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/619,907 07/11/2003		William Vincent Holt	P68318US1	7320
7590 11/17/2005		SEQUENCE LISTING	EXAMINER	
Jacobson Holman PLLC 400 Seventh Street, N.W.			AFREMOVA, VERA	
Washington, DC 20004			ART UNIT	PAPER NUMBER
			1651	
		JACOBSON HOLMAN PLLC	DATE MAILED: 11/17/2005	5
		Response Due On Or Before		
		Month Day Year		

Please find below and/or attached an Office communication concerning this application or proceeding.





## UNITED STATES DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

APPLICATION NO. CONTROL NO.

**FILING DATE** 

FIRST NAMED INVENTOR / PATENT IN REEXAMINATION ATTORNEY DOCKET NO.

10/619,907 7/11/2003

HOLT et al

**EXAMINER** 

Afremore

Vera **ART UNIT** 

**PAPER** 

160

11102005

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

## **Commissioner for Patents**

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth below or on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

This application contains sequence disclosures with 10 amino acids in claims 17, 47, 51 and 55 and also in specification, for example: page 14, line 1.

Applicant is given ONE MONTH, or THIRTY DAYS, whichever is longer, from the mailing date of this letter within which to comply with the sequence rules, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a). In no case may an applicant extend the period for reply beyond the SIX MONTH statutory period. Direct the reply to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the reply.

For questions regarding compliance with these requirements, please contact: TC1600 customer service at (571) 272-1600, and OIPE at (571) 272-4000.

Any inquiry concerning this communication from the examiner should be directed to Vera Afremova whose telephone number is (571) 272-0914. The examiner can normally be reached from Monday to Friday from 9.30 am to 6.00 pm. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Wityshyn can be reached at (571) 272-0926. The fax phone number for the TC 1600 where this application or proceeding is assigned is (571) 273-8300. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Technology center 1600, telephone number is (571) 272-1600.

Vera Afremova AU 1651

November 11, 2005

VERA AFREMOVA PRIMARY EXAMINER

V. Afn





## UNITED STATES DEPARTMENT OF COMMERCE

Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS

APPLICATION NUMBER

FILING/RECEIPT DATE

FORMPTO-1661(Rev. 7/97)

FIRST NAMED APPLICANT

ATTY. DOCKET NO /TITLE

2003

Holt Hal.

DATE MAILED:

## NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with

	the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):
	1. This application fails to comply with the requirements of 37 CFR 1.821–1.825.
	2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).
	<ul> <li>3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).</li> </ul>
	4. A copy of the "Sequence Listing" in computer readable form has been submitted. The content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked—up copy of the "Raw Sequence Listing."
٠	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
	6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).
	☐ 7. OTHER:
<b>→</b>	APPLICANT MUST PROVIDE:  An initial or substitute computer readable form (CRF) copy of the "Sequence Listing."  An initial or substitute paper copy of the "Sequence Listing," as well as an amendment directing its entry into the specification.  A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).
	FOR QUESTIONS REGARDING COMPLIANCE WITH THESE REQUIREMENTS, PLEASE CONTACT:  For Rules Interpretation, call (703) 308–1123.  For CRF submission help, call (703) 368–4212.  For Patentin software help, call (703) 308–6856.
	Customer Service Center Initial Patent Examination Division (703) 308–1202 > (571) - 272 - 4000 V.

. August 2001

PART 1 - ATTORNEY/APPLICANT COPY